A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

June 12, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Breast Neoplasm
Trial Locations (21)

55072

RECRUITING

Essentia Health Sandstone, Sandstone

55362

RECRUITING

MMCORC CentraCare Monticello Cancer Center, Monticello

55731

RECRUITING

Essentia Health Ely Clinic, Ely

RECRUITING

Fairview Northland Medical Center, Princeton

55744

RECRUITING

Fairview Grand Itasca Clinic & Hospital, Grand Rapids

55746

RECRUITING

Essentia Health Hibbing Clinic, Hibbing

RECRUITING

Fairview Range Medical Center, Hibbing

55767

RECRUITING

Essentia Health Moose Lake, Moose Lake

55792

RECRUITING

Essentia Health Virginia Clinic, Virginia

55805

RECRUITING

Essentia Health Cancer Center, Duluth

55905

RECRUITING

Mayo Clinic in Rochester, Rochester

56187

RECRUITING

Sanford Health Worthington, Worthington

56401

RECRUITING

Essentia Health Saint Joseph's Medical Center, Brainerd

56425

RECRUITING

Essentia Health Baxter Clinic, Baxter

56431

RECRUITING

Riverwood Healthcare Center, Aitkin

56470

RECRUITING

Essentia Health - Park Rapids, Park Rapids

56501

RECRUITING

Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes

56542

RECRUITING

Essentia Health - Fosston, Fosston

56636

RECRUITING

Essentia Health - Deer River Clinic, Deer River

56649

RECRUITING

Essentia Health - International Falls Clinic, International Falls

56701

RECRUITING

Sanford Health Thief River Falls Clinic, Thief River Falls

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05889988 - A Study of Ado-trastuzumab Emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients | Biotech Hunter | Biotech Hunter